Emma T. Bowden
YOU?
Author Swipe
View article: Supplementary Figure 4 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i>
Supplementary Figure 4 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i> Open
PDF file - 1.84 MB, Pericyte coverage on tumor microvessels did not associate with the tumor resistance to bevacizumab (bev). Fresh frozen tumor samples were taken from Figure 2D and double stained for CD31 (green) and the pericytic marker…
View article: Supplementary Figure 6 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i>
Supplementary Figure 6 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i> Open
PDF file - 740K, Neither anti-EphrinB2 nor sEphB4 affected the growth of U87-EV tumors in vivo. Compared to the control, neutralizing anti-EphrinB2 antibody (B2) alone (blue arrowhead) did not affect the tumor growth. Also, combined anti-E…
View article: Supplementary Figure 3 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i>
Supplementary Figure 3 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i> Open
PDF 584K, Combination therapy by blockade of both Notch signaling and the VEGF pathway displayed a synergistic therapeutic efficacy in HT1080 xenografted tumors. Single therapy with either DBZ or bevacizumab did not affect tumor growth and…
View article: Supplementary Figure 6 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i>
Supplementary Figure 6 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i> Open
PDF file - 740K, Neither anti-EphrinB2 nor sEphB4 affected the growth of U87-EV tumors in vivo. Compared to the control, neutralizing anti-EphrinB2 antibody (B2) alone (blue arrowhead) did not affect the tumor growth. Also, combined anti-E…
View article: Supplementary Figure 1 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i>
Supplementary Figure 1 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i> Open
PDF file - 473K, Blockade of Notch signaling in endothelial cells by DBZ in vitro. Western blotting showed that the protein levels of activated Notch intracellular domain (NICD) and Hes-1 were significantly reduced by DBZ in human umbilica…
View article: Supplementary Figure 3 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i>
Supplementary Figure 3 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i> Open
PDF 584K, Combination therapy by blockade of both Notch signaling and the VEGF pathway displayed a synergistic therapeutic efficacy in HT1080 xenografted tumors. Single therapy with either DBZ or bevacizumab did not affect tumor growth and…
View article: Supplementary Figure 2 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i>
Supplementary Figure 2 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i> Open
PDF 712K, In vivo expression of mHey1, a downstream target of Notch signaling in the mouse stroma/ECs of U87 tumors. The relative expression of mHey1 in tumor tissues was analyzed by qPCR against mRNA extracted from xenograft tumors using …
View article: Supplementary Figure 5 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i>
Supplementary Figure 5 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i> Open
PDF file - 4.04 MB, DLL4 downregulated the expression of VEGFR3 in human microvascular EC in vitro and in xenograft tumor in vivo. (A). The expression of VEGFR3 at a mRNA level was decreased in human micrcovascular EC (hMEC-1) cultured in …
View article: Supplementary Figure 4 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i>
Supplementary Figure 4 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i> Open
PDF file - 1.84 MB, Pericyte coverage on tumor microvessels did not associate with the tumor resistance to bevacizumab (bev). Fresh frozen tumor samples were taken from Figure 2D and double stained for CD31 (green) and the pericytic marker…
View article: Supplementary Figure 2 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i>
Supplementary Figure 2 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i> Open
PDF 712K, In vivo expression of mHey1, a downstream target of Notch signaling in the mouse stroma/ECs of U87 tumors. The relative expression of mHey1 in tumor tissues was analyzed by qPCR against mRNA extracted from xenograft tumors using …
View article: Supplementary Materials and Methods from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i>
Supplementary Materials and Methods from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i> Open
PDF file - 77K
View article: Data from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i>
Data from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i> Open
Resistance to VEGF inhibitors is emerging as a major clinical problem. Notch signaling has been implicated in tumor angiogenesis. Therefore, to investigate mechanisms of resistance to angiogenesis inhibitors, we transduced human glioblasto…
View article: Supplementary Materials and Methods from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i>
Supplementary Materials and Methods from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i> Open
PDF file - 77K
View article: Data from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i>
Data from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i> Open
Resistance to VEGF inhibitors is emerging as a major clinical problem. Notch signaling has been implicated in tumor angiogenesis. Therefore, to investigate mechanisms of resistance to angiogenesis inhibitors, we transduced human glioblasto…
View article: Supplementary Figure 1 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i>
Supplementary Figure 1 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i> Open
PDF file - 473K, Blockade of Notch signaling in endothelial cells by DBZ in vitro. Western blotting showed that the protein levels of activated Notch intracellular domain (NICD) and Hes-1 were significantly reduced by DBZ in human umbilica…
View article: Supplementary Figure 5 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i>
Supplementary Figure 5 from DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy <i>In Vivo</i> Open
PDF file - 4.04 MB, DLL4 downregulated the expression of VEGFR3 in human microvascular EC in vitro and in xenograft tumor in vivo. (A). The expression of VEGFR3 at a mRNA level was decreased in human micrcovascular EC (hMEC-1) cultured in …